Roche’s most advanced obesity drug allowed patients in a Phase 2 trial who took it for nearly a year to lose 18.3% of their weight after correcting for placebo, the Swiss pharma
Takeda is ‘not in favor’ of Trump’s MFN deals, CEO-designate says
Takeda’s incoming CEO took a firm stance against President Donald Trump’s “most favored nation” deals with drugmakers on Thursday, while Sanofi and Roche shared new


